Sugi Predict

Sugi Predict / Compounds / SCHEMBL14749181

SCHEMBL14749181

SCHEMBL14749181

COc1c(N2C[C@@H]3CCCN(C)[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.70
▸ ALDH1A1 P00352 5/20 0.70
▸ HPGD P15428 4/20 0.70
▸ HSD17B10 Q99714 2/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ KCNH2 Q12809 5/20 0.66
▸ POLB P06746 3/20 0.66
▸ TDP1 Q9NUW8 2/20 0.66
▸ OPRM1 P35372 2/20 0.66
▸ PRKD3 O94806 1/20 0.66
▸ ALOX15 P16050 1/20 0.66
▸ CLK2 P49760 1/20 0.66
▸ CLK4 Q9HAZ1 1/20 0.66
▸ LMNA P02545 2/20 0.60
▸ CYP2C19 P33261 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ ATM Q13315 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.54
▸ CHRM2 P08172 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30388535 1.00 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL680655 1.00 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL14749183 0.93 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL28417070 0.92 KDM4E (0.71) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL28408497 0.92 KDM4E (0.70) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL680228 0.91 ALDH1A1 (0.57) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL8982806 0.91 ALDH1A1 (0.57) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL9570692 0.91 ALDH1A1 (0.57) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL2739042 0.90 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL22499634 0.90 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112641773-A Composition containing heterocyclic compound and use thereof 黄泳华 2021-04-13 — — CN claimed
CN-110974968-B Quinolone compound-containing composition and application thereof 中山万远新药研发有限公司 2021-03-26 — — CN claimed
CN-111514125-B Composition containing quinolone compound and edetic acid compound 中山万汉制药有限公司 2021-03-23 — — CN claimed
CN-111514125-A Composition containing quinolone compound and edetic acid compound 中山万汉制药有限公司 2020-08-11 — — CN claimed
CN-111150734-A Compositions containing mixtures of quinolinone derivatives and uses thereof 黄泳华 2020-05-15 — — CN claimed
CN-110974968-A Quinolone compound-containing composition and application thereof 中山万远新药研发有限公司 2020-04-10 — — CN claimed
CN-111024831-B Method for separating moxifloxacin hydrochloride and impurities thereof by high performance liquid chromatography 江苏正大丰海制药有限公司 2023-05-02 — — CN disclosed
CN-112641773-A Composition containing heterocyclic compound and use thereof 黄泳华 2021-04-13 — — CN disclosed
CN-111514125-B Composition containing quinolone compound and edetic acid compound 中山万汉制药有限公司 2021-03-23 — — CN disclosed
CN-111514125-A Composition containing quinolone compound and edetic acid compound 中山万汉制药有限公司 2020-08-11 — — CN disclosed
CN-111150734-A Compositions containing mixtures of quinolinone derivatives and uses thereof 黄泳华 2020-05-15 — — CN disclosed
EP-2551268-B1 Process for the preparation of moxifloxacin hydrochloride and intermediates thereof FIS FABBRICA ITALIANA SINTETICI SPA (IT) 2017-01-18 — — EP disclosed
US-8975408-B2 Moxifloxacin hydrochloride compounds and intermediates and methods for making same F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) 2015-03-10 — — US disclosed
US-8975408-B2 Moxifloxacin hydrochloride compounds and intermediates and methods for making same F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) 2015-03-10 — — US disclosed
US-20140135501-A1 MOXIFLOXACIN HYDROCHLORIDE COMPOUNDS AND INTERMEDIATES AND METHODS FOR MAKING SAME F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2014-05-15 — — US disclosed
US-20140135501-A1 MOXIFLOXACIN HYDROCHLORIDE COMPOUNDS AND INTERMEDIATES AND METHODS FOR MAKING SAME F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2014-05-15 — — US disclosed
US-8664398-B2 Moxifloxacin hydrochloride compounds and intermediates and methods for making same F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) 2014-03-04 — — US disclosed
US-8664398-B2 Moxifloxacin hydrochloride compounds and intermediates and methods for making same F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) 2014-03-04 — — US disclosed
US-20130059880-A1 MOXIFLOXACIN HYDROCHLORIDE COMPOUNDS AND INTERMEDIATES AND METHODS FOR MAKING SAME F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2013-03-07 — — US disclosed
US-20130059880-A1 MOXIFLOXACIN HYDROCHLORIDE COMPOUNDS AND INTERMEDIATES AND METHODS FOR MAKING SAME F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135501-A1 MOXIFLOXACIN HYDROCHLORIDE COMPOUNDS AND INTERMEDIATES AND METHODS FOR MAKING SAME CYP3A7, CYP2C9, CYP3A5 KDM4E 3341/4885ALDH1A1 1626/4885HPGD 394/4885
US-20130059880-A1 MOXIFLOXACIN HYDROCHLORIDE COMPOUNDS AND INTERMEDIATES AND METHODS FOR MAKING SAME CYP3A7, CYP2C9, CYP3A5 KDM4E 3341/4885ALDH1A1 1626/4885HPGD 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.